In the 12 years since its launch in 2004, Gendicine has published results from more than 30 clinical trials of rAd-p53 and rAd-p53 in combination with other therapeutic regimens for the treatment of HNSCC and other cancers, and to date, Gendicine has been used clinically in China to treat more than 30,000 patients [42]. This evidence concerns the gene TP53 and cancer.